This content is machine translated TYK2 inhibition in psoriasis What’s new? The JAK-STAT pathway mediates a variety of proinflammatory responses through Janus kinases (JAK)1-3 andtyrosine kinase-2 (TYK2).Deucravacitinib selectively inhibits TYK2 and was shown to be effective and safe in patients with…
View Post 3 min This content is machine translated Plaque psoriasis New “Real World” Study on Tildrakizumab In a retrospective study of 30 patients with moderate to severe plaque psoriasis, the use of the IL-23 inhibitor tildrakizumab was shown to be effective and safe in clinical practice.…
View Post 3 min This content is machine translated Plaque psoriasis Current 5-year data on secukinumab A long-term extension analysis of the ERASURE and FIXTURE studies recently published in the British Journal of Dermatology demonstrates the long-lasting efficacy and safety of secukinumab in patients with moderate-to-severe…
View Post 3 min This content is machine translated Plaque psoriasis TYK2 inhibition shows great therapeutic potential Psoriasis is nowadays understood as a systemic disease, which is based on chronic inflammation. Research into the etiopathogenesis, as well as the establishment of new active substances, is progressing rapidly.…
View Post 8 min This content is machine translated Plaque psoriasis Updated guideline recommendations for children and adolescents Early treatment in children and adolescents with psoriasis is an important supply target. The updated s2k guideline provides evidence-based decision support for the selection of appropriate therapy. In the new edition…
View Post 4 min This content is machine translated Moderate to severe plaque psoriasis High patient satisfaction thanks to rapid and sustained efficacy of ixekizumab From the patient’s point of view, a rapid onset of action is one of the most important treatment goals, along with appearance-free skin. Both the data from the UNCOVER-3 study…
View Post 3 min This content is machine translated Apremilast “Real-world evidence” in plaque psoriasis with limited skin involvement. The results of the international multicenter study APPRECIATE show a significant symptom reduction including skin involvement of specific sites. In addition, a significant improvement in quality of life was measurable.
View Post 3 min This content is machine translated Risankizumab as a therapeutic option “Real life” interim balance: PASI 100 – realistic target Risankizumab has been approved in Switzerland since April 2019 for moderate to severe plaque psoriasis after unsuccessful therapy with conventional systemic treatment. The high and long-lasting efficacy with rapid response…
View Post 9 min This content is machine translated Plaque psoriasis Current therapeutic aspects An update on therapies currently available for plaque psoriasis. The introduction of biologics has changed the way patients with moderate to severe psoriasis are treated – with far-reaching implications for…
View Post 3 min This content is machine translated Psoriatic Arthritis Therapeutic options and results There are increasing signs of success in the treatment not only of rheumatoid arthritis (RA), but also of psoriatic arthritis (PsA). At the ACR Congress in San Diego, researchers were…
View Post 5 min This content is machine translated Open questions in psoriasis What does the consensus say? The therapeutic goal in moderate to severe plaque psoriasis is to relieve patients of their skin symptoms as much as possible (PASI ≥75%). If this does not succeed within certain…
